About
Research
Products
Investors
Careers
Agenda
fr
Press Releases
Our latest news and press releases
All
2018
2017
2016
2015
2014
04
Sep
2017
22:30 E.S.T.
Cellectis to Participate in Upcoming Investor Conferences
Read more
04
Sep
2017
22:15 E.S.T.
Cellectis Reports Clinical Hold of UCART123 Studies
Read more
17
Aug
2017
16:30 E.S.T.
Cellectis’ UCART123 Administered to First Patient with BPDCN in Phase I Clinical Trial at MD Anderson Cancer Center
Read more
02
Aug
2017
16:30 E.S.T.
Cellectis Reports Financial Results for 2nd Quarter and First Six Months 2017
Read more
25
Jul
2017
16:01 E.S.T.
Calyxt Announces Full Exercise of Over-Allotment Option and Closing of its Initial Public Offering
Read more
24
Jul
2017
16:30 E.S.T.
Cellectis Granted Patent for CRISPR Use in T-Cells
Read more
19
Jul
2017
18:54 E.S.T.
Calyxt Announces Pricing of $56.0 Million Initial Public Offering
Read more
10
Jul
2017
07:08 E.S.T.
Calyxt Announces Proposed Initial Public Offering of $100.0 Million
Read more
28
Jun
2017
16:30 E.S.T.
Cellectis Appoints Rainer Boehm, M.D. and Hervé Hoppenot to Board of Directors
Read more
27
Jun
2017
16:30 E.S.T.
First in Human Administration of UCART123 in Cellectis’ AML Phase I Clinical Trial at Weill Cornell Medicine, NewYork-Presbyterian Hospital
Read more
Prev
3
4
5
6
7
Next